Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study
| Autor: | Anna-Karin Elf, Daniel Granfeldt, Åse Björstad, Sylvie Gabriel, Jerome Dinet, Viktor Johanson, Aude Houchard, Anthony Berthon, Ingela Björholt, Eva Lesén |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Total cost Population Population based 03 medical and health sciences Indirect costs 0302 clinical medicine Cost of Illness Stomach Neoplasms Internal medicine Intestinal Neoplasms Cost of illness Humans Medicine Registries Neoplasm Metastasis Medical prescription education Malignant Carcinoid Syndrome Sweden Sickness absence education.field_of_study business.industry Health Care Costs Middle Aged Patient Acceptance of Health Care medicine.disease Pancreatic Neoplasms Neuroendocrine Tumors Oncology 030220 oncology & carcinogenesis Female Health Expenditures business Carcinoid syndrome |
| Zdroj: | European Journal of Cancer Care. 28:e12983 |
| ISSN: | 0961-5423 |
| DOI: | 10.1111/ecc.12983 |
| Popis: | The objective was to estimate the cost-of-illness of grades 1 and 2 metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in Sweden in 2013 in a population-based study including all patients diagnosed between 2005 and 2013. Data were obtained from national registers, and patients who utilised healthcare resources due to metastatic GEP-NETs in 2013 were included. The study included 478 patients (mean age 64 [SD=11] years, 51% men). The majority (80%) had small intestinal NET, 10% had pancreatic NET, and 41% had carcinoid syndrome. The total cost-of-illness was €12,189,000 in 2013, of which direct costs constituted 77% and costs from production loss constituted 22%. The largest contributor to the direct medical costs was prescription drugs (54%; primarily somatostatin analogues [91% of the total drug cost]). Production loss due to sickness absence constituted 52% of the total costs of production loss. The total annual cost per patient was €25,500. By patient group, the cost was €24,800 (95% CI €21,600-€28,100) for patients with small intestinal NET, €37,300 (95% CI €23,300-€51,300) for those with pancreatic NET and €18,600 (95% CI €12,600-€24,500) for patients with other GEP-NETs. To conclude, the total annual cost of grades 1 and 2 metastatic GEP-NETs in Sweden was €25,500 per patient and year. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|